Q-omics provides the consensus-scored CASC18 profile across patient tissues and cancer cell-line models. CASC18 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, CASC18 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, CASC18 RNA expression shows 11,691 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight STAD, COAD, and PDAC as cancer lineages where CASC18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CASC18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CASC18 survival associations across molecular data types. CASC18 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CASC18 RNA expression–survival associations across cancer types. High CASC18 expression shows unfavorable associations in STAD, UCEC and OV, but favorable associations in LUAD, UCS and ESCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for CASC18 RNA expression.
This table summarizes CASC18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CASC18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CASC18 shows lower tumor expression in COAD, KICH, KIRC and READ and higher tumor expression in HNSC and LUSC. The COAD box plot shows higher CASC18 RNA expression in normal versus tumor tissue (log2 FC = −0.543, t-test p < 0.001).
This table shows molecular features associated with CASC18 in patient tissues and cancer cell lines. In patient samples, CASC18 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
